News

Superstar investor Cathie Wood is increasing her bet on a cutting-edge technology that could transform the treatment of many diseases. I'm talking about gene editing.

Wood has been progressively

Novavax (NASDAQ: NVAX) shares have brought investors extremely good times and extremely bad times. They soared back in 2020 on hopes the biotech would score a win with its coronavirus vaccine

A potential upswing of COVID was the impetus behind a blast of interest in Novavax (NASDAQ: NVAX) stock on Tuesday.

That morning, it was reported by various media outlets that first lady Jill Biden

Shares of Insmed (NASDAQ: INSM) were soaring 17.1% higher as of 11:27 a.m. ET on Tuesday. The big gain came after the company announced positive top-line results from its late-stage Arise clinical

The aim of growth investing is to build significant wealth. Targeting companies that are briskly growing revenue can be a lucrative approach to investing.

In the past five years, the genetic

There is some good news and bad news for fans of Cathie Wood. The good news for the co-founder CEO of the Ark Invest family of exchange-traded funds (ETFs) is that her largest fund -- with more than

Concerns around COVID-19 are diminishing but they are not going away entirely. New variants are emerging and case numbers have been climbing.

One company that continues to work on developing an

The latest rise in COVID-19 statistics is bringing investors back to coronavirus stocks. That, combined with a top-down effort to develop an updated vaccine and get it in the arms of as many

Growth stocks have lost momentum in August after a strong start to the year. The market is worried about the impact of a possible recession, high inflation, and high interest rates on the future

Despite what many people think, the pandemic isn't officially over yet. And while the world has made tremendous progress, the coronavirus continues to cause problems. COVID-19 cases and

If Wall Street is having a back-to-school sale, Cathie Wood is shopping. The widely followed growth investor who leads Ark Invest did a fair amount of buying on Tuesday. She publishes her daily

Unprofitable clinical-stage biotechs have lost their appeal in the past year, given the challenging economic and market conditions we still haven't entirely left behind. That's why companies such as

By some estimates, the market for nonalcoholic steatohepatitis (NASH) medicines will be worth a startling $108 billion by 2030, even though no drugs are yet on the market for it. That makes it a

Investors in Novavax (NASDAQ: NVAX) haven't had much to celebrate recently, but the stock is rocketing higher on Tuesday. As of 11:30 a.m. ET, Novavax shares were up more than 17%, despite the

Don't let anyone tell you that you must have a boatload of money to get started investing in stocks. It's simply not true. Sure, you'll need some upfront cash. However, even a modest amount is

Novavax (NASDAQ: NVAX) has gone from a pandemic darling to a bust, with its shares falling by a whopping 83% over the past 12 months. The hope and optimism surrounding the stock has faded. Earlier

Shares of BioLife Solutions (NASDAQ: BLFS) were down more than 37% for the week, as of 3:15 p.m. ET on Friday, according to data provided by S&P Global Market Intelligence. The healthcare company's

As conventional investment wisdom has it, it's best to buy low and sell high. However, that only works when you have solid reasons to believe a company's shares will bounce back meaningfully after a

There's nothing like a surge in a deadly disease to encourage investors back into a noted healthcare stock. This dynamic benefited biotech Novavax (NASDAQ: NVAX) on Thursday.

It was also on the back

Shares of MacroGenics (NASDAQ: MGNX) were up more than 24% as of 11:45 a.m. on Thursday after the biotech company announced second-quarter earnings. The stock is down more than 7% so far this year.

Image source: The Motley Fool.

MacroGenics (NASDAQ: MGNX)Q2 2023 Earnings CallAug 09, 2023, 4:30 p.m. ET

Operator

Continue reading

Source Fool.com